Title : Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.

Pub. Date : 2015 Oct

PMID : 26238121






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: Roxadustat transiently and moderately increased endogenous erythropoietin and reduced hepcidin. roxadustat erythropoietin Homo sapiens